UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------
FORM 8-K
-----------------
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report: July 19, 2006
THERAGENICS CORPORATION(R)
(Exact name of registrant as specified in charter)
Delaware 000-15443 58-1528626
(State of incorporation) (Commission File Number) (IRS Employer
Identification No.)
5203 Bristol Industrial Way
Buford, Georgia 30518
(Address of principal executive offices / Zip Code)
(770) 271-0233
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
- --------------------------------------------------------------------------------
Item 2.02. Results of Operations and Financial Condition.
On July 19, 2006, Theragenics Corporation (the "Company") issued a press
release regarding its consolidated financial results for the quarter ended July
2, 2006. The Company's press release is furnished as Exhibit 99.1 to this
Current Report on Form 8-K.
The information in this Current Report on Form 8-K and the Exhibit
attached hereto shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933 or the Exchange Act, regardless of
any general incorporation language in such filing.
- --------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Theragenics Corporation
(Registrant)
Dated: July 19, 2006
By: /s/ M. Christine Jacobs
-----------------------
M. Christine Jacobs
Chief Executive Officer
- --------------------------------------------------------------------------------
EXHIBIT INDEX
Exhibit No. Description
99.1 Press Release, dated July 19, 2006 of Theragenics Corporation.